Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zhou

Showing results (1101-1110 of 1,424) with videos related to

Pageof 143
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsJ C-H Yang, L V Sequist, C Zhou, et al.
Plos One|September 30, 2020
Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: A proposal for the COVID-AID risk toolKaveh Hajifathalian, Reem Z Sharaiha, Sonal Kumar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2015
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE studyY-L Wu, C Zhou, C-K Liam, et al.
Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics|June 21, 2019
[Clinical analysis of 555 outpatients with hand, foot and mouth diseases caused by different enteroviruses]P Cui, Y Li, C C Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G Chen, J Feng, C Zhou, et al.
Nature|May 29, 2024
A site-resolved two-dimensional quantum simulator with hundreds of trapped ionsS-A Guo, Y-K Wu, J Ye, et al.
Annals of the American Thoracic Society|September 8, 2025
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach StudyPedro Miranda Afonso, Grace C Zhou, Weiji Su, et al.
Cancer|July 2, 2026
Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor StudyDuncan C Ramsey, David S Shulman, Grace C Zhou, et al.
British Journal of Cancer|October 3, 2013
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effectsN L Henry, H-P Chan, J Dantzer, et al.
Pageof 143

Showing results (1101-1110 of 1,424) with videos related to

Sort By:
Pageof 143
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsJ C-H Yang, L V Sequist, C Zhou, et al.
Plos One|September 30, 2020
Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: A proposal for the COVID-AID risk toolKaveh Hajifathalian, Reem Z Sharaiha, Sonal Kumar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2015
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE studyY-L Wu, C Zhou, C-K Liam, et al.
Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics|June 21, 2019
[Clinical analysis of 555 outpatients with hand, foot and mouth diseases caused by different enteroviruses]P Cui, Y Li, C C Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G Chen, J Feng, C Zhou, et al.
Nature|May 29, 2024
A site-resolved two-dimensional quantum simulator with hundreds of trapped ionsS-A Guo, Y-K Wu, J Ye, et al.
Annals of the American Thoracic Society|September 8, 2025
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach StudyPedro Miranda Afonso, Grace C Zhou, Weiji Su, et al.
Cancer|July 2, 2026
Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor StudyDuncan C Ramsey, David S Shulman, Grace C Zhou, et al.
British Journal of Cancer|October 3, 2013
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effectsN L Henry, H-P Chan, J Dantzer, et al.
Pageof 143